Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C45H49N7O11S |
| Molecular Weight | 895.976 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@]4(OC(=O)[C@@H](NC(=O)[C@H](CC1=CNC=N1)NC(=S)NC2=CC=C(O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)[C@@H]3O)C=C2)C(C)C)C(=O)OCC5=C4C=C6N(CC7=CC8=C(C=CC=C8)N=C67)C5=O
InChI
InChIKey=SLOJCSGNHWIKIG-JNYZSSQASA-N
InChI=1S/C45H49N7O11S/c1-6-45(30-17-33-35-25(15-24-9-7-8-10-31(24)49-35)19-52(33)40(56)29(30)20-60-43(45)58)63-41(57)34(22(2)3)51-39(55)32(16-27-18-46-21-47-27)50-44(64)48-26-11-13-28(14-12-26)62-42-37(54)38(59-5)36(53)23(4)61-42/h7-15,17-18,21-23,32,34,36-38,42,53-54H,6,16,19-20H2,1-5H3,(H,46,47)(H,51,55)(H2,48,50,64)/t23-,32-,34-,36+,37-,38+,42+,45-/m0/s1
| Molecular Formula | C45H49N7O11S |
| Molecular Weight | 895.976 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Afeletecan (Bay 38-3441) is a camptothecin glycoconjugate which stabilizes the active lactone form of camptothecin and allows selective uptake into tumor cells. Afeletecan is a topoisomerase inhibitor. Afeletecan was in phase I clinical trials with Bayer for the treatment of cancer; however, development appears to have been discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Gateways to clinical trials. | 2003 Jul-Aug |
|
| Gateways to clinical trials. March 2003. | 2003 Mar |
|
| Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. | 2005 Oct |
Patents
Sample Use Guides
Solid tumors: A total of 81 patients with advanced solid tumors were treated with BAY 38-3441 either at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600 mg/m2/day for 1 day every 3 weeks (single-dose schedule), or at doses of 126, 189, 246, 320 and 416 mg/m2/day once daily for three consecutive days every 3 weeks (3-day schedule). 3-day schedule for BAY 38-3441 at a dose of 320 mg/m2/day as 30-min infusions for further phase II studies was recommended.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:13:57 GMT 2023
by
admin
on
Fri Dec 15 16:13:57 GMT 2023
|
| Record UNII |
IX0QAD6RD2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2843
Created by
admin on Fri Dec 15 16:13:57 GMT 2023 , Edited by admin on Fri Dec 15 16:13:57 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9941008
Created by
admin on Fri Dec 15 16:13:57 GMT 2023 , Edited by admin on Fri Dec 15 16:13:57 GMT 2023
|
PRIMARY | |||
|
215604-75-4
Created by
admin on Fri Dec 15 16:13:57 GMT 2023 , Edited by admin on Fri Dec 15 16:13:57 GMT 2023
|
PRIMARY | |||
|
C79725
Created by
admin on Fri Dec 15 16:13:57 GMT 2023 , Edited by admin on Fri Dec 15 16:13:57 GMT 2023
|
PRIMARY | |||
|
100000178144
Created by
admin on Fri Dec 15 16:13:57 GMT 2023 , Edited by admin on Fri Dec 15 16:13:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105857
Created by
admin on Fri Dec 15 16:13:57 GMT 2023 , Edited by admin on Fri Dec 15 16:13:57 GMT 2023
|
PRIMARY | |||
|
IX0QAD6RD2
Created by
admin on Fri Dec 15 16:13:57 GMT 2023 , Edited by admin on Fri Dec 15 16:13:57 GMT 2023
|
PRIMARY | |||
|
7968
Created by
admin on Fri Dec 15 16:13:57 GMT 2023 , Edited by admin on Fri Dec 15 16:13:57 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
